Clinical Trial Update: Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of dovitinib in BCG-refractory urothelial carcinoma with FGFR3 alterations; status terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: Noah Hahn, M.D. | Conditions: Bladder Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-08-22